title: Calcimimetics and bone mineral density in renal transplant patients with persistent secondary hyperparathyroidism.
abstract: BACKGROUND
  The persistence of secondary hyperparathyroidism plays an important role in posttransplant bone loss. Calcimimetics are efficient to control metabolic alterations associated with this problem, but there are few publications that assess their effects on bone density.
  
  
  METHODS
  This prospective study assessed the effects of a single daily dose of cinacalcet on calcemia, phosphatemia, parathyroid hormone (PTH), and bone densitometry (femur and spine) values of 27 renal transplant patients with stable kidney function, calcium > 10.5 mg/dL, and PTH > 65 pg/mL.
  
  
  RESULTS
  A preliminary study after 6 months showed decreased calcemia (11.05 +/- 0.5 to 10.18 +/- 0.6 mg/dL; P < .0001), reduced levels of intact PTH (iPTH; 258 +/- 104 to 209.61 +/- 127 pg/mL; P < .05), and increased phosphatemia (2.38 +/- 0.45 to 2.54 +/- 0.3 mg/dL; P < .05). We also observed an increase in femoral neck bone mass with improved T score (-1.36 +/- 1.19 to -1.05 +/- 0.84 g/cm(2); P < .05).
  
  
  CONCLUSIONS
  Cinacalcet was effective in the management of posttransplant persistent secondary hyperparathyroidism, resulting in decreased calcemia and iPTH, while also improving femoral neck bone loss. Longer-term studies with control groups are needed to determine the drug's influence on overall bone mineral density.
authors.affiliation: Nephrology, Hospital Universitario Virgen del Rocio, Seville, Spain.
authors.forename: F J
authors.initials: FJ
authors.lastname: Toro Prieto
authors.forename: G
authors.initials: G
authors.lastname: Bernal Blanco
authors.forename: M
authors.initials: M
authors.lastname: Navarro García
authors.forename: V
authors.initials: V
authors.lastname: Cabello Chaves
authors.forename: R
authors.initials: R
authors.lastname: Garcíajiménez
authors.forename: P
authors.initials: P
authors.lastname: Pereira Palomo
authors.forename: M A
authors.initials: MA
authors.lastname: Gentil Govantes
mesh_terms: D000328:Adult; D000368:Aged; D015519:Bone Density / Q000187:drug effects; D002118:Calcium / Q000097:blood / Q000652:urine; D002574:Cervical Vertebrae / Q000473:pathology; D000069449:Cinacalcet; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006934:Hypercalcemia / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use*; D010281:Parathyroid Hormone / Q000097:blood; D011446:Prospective Studies; D013131:Spine / Q000473:pathology
chemical_list: D009281:Naphthalenes; D010281:Parathyroid Hormone; D002118:Calcium; D000069449:Cinacalcet